肾上腺皮质癌发病率、治疗与生存的时间趋势:全国性研究
该研究纳入荷兰1993至2020年685例成人肾上腺皮质癌患者,基于全国前瞻性癌症登记分析发病率、治疗与生存趋势。年龄标化发病率稳定在1.62/百万人年,III期诊断比例从13%升至25%,IV期5年生存从3%升至11%。集中化诊疗、肾上腺切除术和米托坦治疗与生存改善相关。
要点
- 肾上腺皮质癌年龄标化发病率稳定在1.62/百万人年
- IV期5年生存从1993-1996年的3%升至2017-2020年的11%
- 集中化诊疗、肾上腺切除术和米托坦治疗与生存改善相关
核心结论
- 肾上腺皮质癌年龄标化发病率随时间保持稳定。
- I-III期5年生存保持稳定,IV期生存随时间增加。
- 集中化诊疗、肾上腺切除术、手术控制疾病、化疗和米托坦治疗与生存增加相关。
研究设计与样本
- 基于荷兰全国前瞻性癌症登记的全国性研究,纳入1993至2020年诊断的685例成人肾上腺皮质癌患者。
主要发现
- 基于欧洲标准人口的年龄标化发病率中位数为1.62/百万人年[0.83-2.11],随时间稳定。
- 诊断时III期比例从13%逐渐增至25%,IV期比例稳定在40%。
- I-II期5年生存稳定在65%,III期稳定在35%,IV期从1993-1996年的3%增至2017-2020年的11%。
- 自2004年荷兰肾上腺网络成立以来,更多患者转诊至专家中心(P < .001),与生存增加相关(校正HR 0.70;95% CI,0.57-0.85)。
- 多变量Cox回归显示肾上腺切除术(校正HR 0.53;95% CI,0.43-0.65)和米托坦治疗(校正HR 0.73;95% CI,0.55-0.98)与所有分期生存增加相关。
关键数值与推荐
- IV期疾病中,肾上腺切除术、手术控制疾病、化疗和米托坦治疗与生存增加相关。
- 仅58%的米托坦使用者达到治疗药物水平,59.5%过早停药。
临床怎么用
- 应推动肾上腺皮质癌患者转诊至专家中心以改善生存。
- 肾上腺切除术和米托坦治疗与生存改善相关,应考虑用于合适患者。
- 需关注米托坦治疗药物监测和依从性,因达标率低且停药率高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to determine time trends in incidence, treatment, and survival of patients with adrenocortical carcinoma in the Netherlands. METHODS: All 685 adult patients with adrenocortical carcinoma diagnosed between 1993 and 2020 in the Netherlands were included, using the nationwide prospective Netherlands Cancer Registry. RESULTS: The median age-adjusted incidence rate based on the European Standard Population was 1.62 per million person-years [0.83-2.11] and was stable over time. We saw a gradual increase in stage III on diagnosis (13%-25%) with a stable proportion of stage IV (40%). The 5-year survival remained stable over time for stage I-II at 65% and stage III at 35%, whereas the survival for stage IV increased from 3% in 1993 through 1996 to 11% in 2017 through 2020. Since the Dutch Adrenal Network was founded in 2004, more patients were referred to an expert center (P < .001), which was associated with increased survival (adjusted HR 0.70; 95% CI, 0.57-0.85). Multivariate Cox regression showed increased survival in all stages when treated with adrenalectomy (adjusted HR 0.53; 95% CI, 0.43-0.65) and mitotane therapy (adjusted HR 0.73; 95% CI, 0.55-0.98). In stage IV disease, adrenalectomy, surgical control of disease, chemotherapy, and mitotane therapy were associated with increased survival. However, only 58% of mitotane users reached a therapeutic drug level and 59.5% discontinued treatment prematurely. CONCLUSION: The incidence of adrenocortical carcinoma is stable over time. The 5-year survival for stage I-III remained stable, whereas the survival for stage IV increased. Factors associated with increased survival are centralization of care, adrenalectomy, surgical control of disease, chemotherapy, and mitotane therapy.
引用
- Steenaard RV, de Wit JS, Rutjens M, et al. Time trends in incidence, treatment, and survival of patients with adrenocortical carcinoma, a nationwide study. J Clin Endocrinol Metab. 2026. PMID: 41765867. doi:10.1210/clinem/dgag088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。